Under the Paperwork Reduction Act of 1995, no persons are required to

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10694436
Filing Date		2003-10-27
First Named Inventor Camp		bell
Art Unit		1614
Examiner Name Shirle		y V. Gembeh
Attorney Docket Number		SIU 7397

					U.S.I	PATENTS			Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue [	Date	Name of Pate of cited Docu	Pages,Columns,Lines where Relevant Passages or Releva Figures Appear				
	1	5122369		1992-06	i-16	Dye					
If you wisl	h to a	dd additional U.S. Pate	nt citatio	n inform	ation pl	ease click the	Add button.	-	Add		
			U.S.P	ATENT	APPLIC	CATION PUBL	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publica Date	tion	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			
	1										
If you wisl	h to a	dd additional U.S. Publi	shed Ap	plication	citation	n information p	lease click the Ad	d button	=		
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove		_
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>		Kind Code <sup>4</sup>	Publication Date	Name of Patente Applicant of cited Document	or ,	vhere Rele	or Relevant	Τē
	1										С
If you wish	h to a	dd additional Foreign P	atent Do	cument	citation	information pl	ease click the Add	button	Add		_
			NON	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove		
Examiner Initials*	Cite No	Include name of the a (book, magazine, jour publisher, city and/or	nal, seri	al, symp	osium,	catalog, etc), o					Τs

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number		10694436
Filing Date			2003-10-27
First Named Inventor Camp		Camp	bell
Art Unit			1614
Examiner Name Shirle		Shirle	y V. Gembeh
Attorney Docket Number		er	SIU 7397

	1		AVARI, S., et al., The Merck Index, An Encyclopedia of Chemicals, Drugs, and Biological pany, Inc., Eleventh Edition, Scientific & Technical Information Center, January, 6, 1993, 1 e							
	2		S, A.E., et al., Effect of Stereoisomers of Sulfur-containing Amino Acids on Local Skin Pro Aerospace Medicine, July, 1967, pp. 708-712	tection in X-rradiated						
	3		DBS, J.B., et al., Treatment of Radiation-Induced alopecia, Head Neck Surg., 1979 Nov-D zz PubMed.	ec., Vol. 2(2), pp. 154,						
If you wish to add additional non-patent literature document citation information please click the Add button Add										
	EXAMINER SIGNATURE									
Evenine	Cian	atura	Data Canaidared							

1 See Kind Codes of USPT/D Patent Documents at year USPT/D,OD/V or MPEP 901.04. <sup>2</sup> Either office that issued the document, by the ho-eleter code (WIPD Standard ST.3). <sup>2</sup> For Justanese patent concurrent, by manufact of the year of the Emporer must procedule the sear insurber of the Emporer must procedule the sear insurber of the patent document.

\* Kind of document by the appropriate symbols as indicated on the document under WIPD Standard ST.16 if possible. <sup>2</sup> Applicant is to place a check mark here if English tanguage the instatution is attacked.

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

### INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 GFR 1.99)

Application Number		10694436
Filing Date		2003-10-27
First Named Inventor Camp		bell
Art Unit		1614
Examiner Name Shirle		y V. Gembeh
Attorney Docket Number		SIU 7397

#### CERTIFICATION STATEMENT

Please see	37	CER	1 97	and	1 02 1	o make t	he annron	riota e	alaction/	el·

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 37 CFF 1.37(e)(1).

#### OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(e).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- \_ ....

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Janet S. Hendrickson/	Date (YYYY-MM-DD)	2007-04-30
Name/Print	Janet S. Hendrickson	Registration Number	55258

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenary Cfing. U.S. Operatment of Commence, P. 0. Box 1450, Alexandria, V.S. 2313-1450. D. ONT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2313-1450.

#### Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
  application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
  disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
  which became abandoned or in which the proceedings were terminated and which application is referenced by either a
  published application, an application open to public inspections or as issued patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.